Results 11 to 20 of about 160,725 (309)

Theranostics for Triple-Negative Breast Cancer

Diagnostics, 2023
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely
Hyeryeon Choi, Kwangsoon Kim
openaire   +3 more sources

MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells

Technology in Cancer Research & Treatment, 2020
Triple-negative breast cancer shows worse outcome compared with other subtypes of breast cancer. The discovery of dysregulated microRNAs and their roles in the progression of triple-negative breast cancer provide novel strategies for the treatment of ...
Guochen Zhang MD, Junlan Wang BS, Ruilin Zheng MD, Beibei Song BS, Li Huang PhD, Yujiang Liu MD, Yating Hao MD, Xiangdong Bai PhD   +7 more
doaj   +1 more source

Phospho-Akt expression is high in a subset of triple negative breast cancer patients [PDF]

, 2014
The most commonly used biomarkers to predict the response of breast cancer patients to therapy are oestrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2).
Baldacchino, Shawn, DeGaetano, James, Scerri, Christian A., Borg, Nigel, Saliba, Christian, Grech, Godfrey, Falzon, Sharon   +6 more
core   +1 more source

Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

World Journal of Surgical Oncology, 2020
Background Metaplastic breast cancer remains poorly characterized given its rarity and heterogeneity. The majority of metaplastic breast cancers demonstrate a phenotype of triple-negative breast cancer; however, differences in clinical outcomes between ...
Evan Morgan, Anupama Suresh, Akaansha Ganju, Daniel G. Stover, Robert Wesolowski, Sagar Sardesai, Anne Noonan, Raquel Reinbolt, Jeffrey VanDeusen, Nicole Williams, Mathew A. Cherian, Zaibo Li, Gregory Young, Marilly Palettas, Julie Stephens, Joseph Liu, Amanda Luff, Bhuvaneswari Ramaswamy, Maryam Lustberg   +18 more
doaj   +1 more source

Characteristics of triple-negative breast cancer [PDF]

Journal of Cancer Research and Clinical Oncology, 2010
Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking similarities with basal-like breast cancers (BBC), so a number of studies considered them being the ...
de Ruijter, Tim C., Veeck, Jurgen, de Hoon, Joep P. J., van Engeland, Manon, Tjan-Heijnen, Vivianne C.   +4 more
openaire   +3 more sources

Differences in breast cancer hormone receptor status in ethnic groups: a London population. [PDF]

, 2013
BACKGROUND: Triple negative breast cancer (TNBC) is associated with different ethnic groups in the United States (US), however this has not previously been examined in a population-based study within the United Kingdom (UK). METHODS: Electronic pathology
Jack, Ruth H, Grocock, Melanie J, Renshaw, Christine, Jack, Ruth H., Davies, Elizabeth A.; id_orcid, Coupland, Victoria H, Møller, Henrik, Davies, Elizabeth A., Moller, Henrik; id_orcid, Coupland, Victoria H., Grocock, Melanie J., M�ller, Henrik, Davies, Elizabeth A, Tutt, Andrew   +13 more
core   +1 more source

miR-331-3p Suppresses Cell Proliferation in TNBC Cells by Downregulating NRP2

Technology in Cancer Research & Treatment, 2020
Purpose: Triple-negative breast cancer is characterized by fast progression with high possible for metastasis and poor survival. Dysfunction of microRNAs plays an important role in the initiation and progression of cancer.
Mingchuan Zhao PhD, Mengmeng Zhang PhD, Zhonghua Tao PhD, Jun Cao PhD, Leiping Wang PhD, Xichun Hu PhD, MD   +5 more
doaj   +1 more source

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings [PDF]

, 2013
Background: TNBC represents a heterogeneous subgroup of BC with poor prognosis and frequently resistant to CT. Material and methods: The relationship between Bcl2 immunohistochemical protein expression and clinicopathological outcomes was assessed in 736
Ball, G, Perry, C, Moseley, P, Madhusudan, S, Chan, SYT, Abdel-Fatah, TMA, Ellis, IO, Dickinson, P   +7 more
core   +1 more source

Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions

Technology in Cancer Research & Treatment, 2020
Background: Triple-negative breast cancer encompasses heterogeneous subtypes. Neoadjuvant chemotherapy is ineffective against some triple-negative breast cancers, while others show a favorable prognosis despite chemoresistance.
Koichi Kubouchi MD, Kyosuke Shimada MD, Takamichi Yokoe MD, Yutaka Tsutsumi MD   +3 more
doaj   +1 more source

MicroRNAs expression in triple negative vs non triple negative breast cancer in Tunisia: interaction with clinical outcome. [PDF]

PLoS ONE, 2014
MicroRNAs are small, non coding regulatory molecules containing approximately 21 to 25 nucleotides. They function as controllers of expression at post transcriptional levels of most human protein-coding genes and play an essential role in cell signaling ...
Imen Medimegh, Ines Omrane, Maud Privat, Nancy Uhrhummer, Hajer Ayari, Fadoua Belaiba, Farhat Benayed, Khaled Benromdhan, Sylvie Mader, Ives-Jean Bignon, Amel Benammar Elgaaied   +10 more
doaj   +1 more source